Orakl Oncology

After a long summer break, Bits in Bio is back in Paris with a bang in November! This time, we're proud to host a unique event to welcome our friends from the Greater Paris University Hospitals - AP-HP, and more specifically their AI labs Bernoulli Lab. This is a unique opportunity to see some of the projects being developed by and for clinicians with members of the Paris tech and biotech community. To join, don't forget to register! We're really happy to organise this edition with Christophe Tallec and BioLabs, Estelle Botbol 🎗️and Speedinvest, Félix Raimundo, PhD (from the other side of the Atlantic) as well as myself for Orakl Oncology.

🚀 We're hiring! As Orakl continues to grow rapidly, we're seeking a dynamic and highly-skilled Chief of Staff to help drive and accelerate our development. If you're passionate about making a meaningful impact and are eager to join an ambitious healthcare start-up on an exciting journey, this role is for you. Know someone who would be a great fit? Please share this opportunity! More information in comment.   #chiefofstaff #startup #techbio #cancer #healthcare #hiring

Are you a #TechBio founder or investor? Join us for breakfast in London on Tuesday, October 8th! 🧬🖥️🥐☕️ Start your day with coffee, pastries, and engaging conversations with fellow founders and investors. Hosting it with HCVC, Speedinvest, and IQ Capital, we're excited to bring together TechBio founders and investors to meet and discuss the latest trends. There are only a few spots left so click the link below to request a seat at the table ASAP ⬇ https://lu.ma/6fgcktsb #AI #ML #compbio #bioinformatics #healthtech #londontech #founders #science #investors Gustave Ronteix, Diane-Laure Pagès, Isabel Zhang, Daria Gherghelas, Kushaal Desai, Alexis Houssou, Estelle Botbol 🎗️, Andrea Zitna

Are you a TechBio founder or investor? Join us for breakfast in London on October 8! 🧬🖥️ Start your day with coffee, pastries, and engaging conversations with fellow founders and investors. Along with our friends at HCVC, IQ Capital, and Orakl Oncology, we're excited to bring together a select group of TechBio founders and investors to meet and discuss the latest trends. Space is very limited so click the link below to request a seat at the table ASAP ⬇ https://lu.ma/6fgcktsb #techbio #healthtech #londontech #founders #venturecapital Daria Gherghelas, Andrea Zitna, Estelle Botbol 🎗️ Hendrik Steenfadt, MD, Gustave Ronteix, Isabel Zhang, Kushaal Desai

🤝 Partnership announcement ✨ We are glad to announce that Orakl Oncology joined RHU ORGANOMIC 🎯 RHU ORGANOMIC aims at using patient derived organoids to predict personalized treatment responses. Led by Fanny Jaulin, PhD, this project brings together top experts and cutting-edge technologies from academic and industrial partners Gustave Roussy, Inserm, Institut Pasteur, CentraleSupélec, Okomera, AstraZeneca, Université Paris-Saclay. 🔎 Initially focused on metastatic colorectal and pancreatic cancers, ORGANOMIC develops innovative tools like Chemogram and Immunogram aiming at identifying tumor vulnerabilities. This will be used to orient patient treatment to improve efficacy and decrease the toxicity of inefficient drugs. Thanks to all partners for your welcoming, we are really excited to work together on great science and innovation for the benefit of patients. Link to the RHU Organomic website and details in comment 👇

🏆 Orakl Oncology is a winner of France Innovation Competitions, “Grand Prix” #iLab!   Yesterday, our CEO Fanny Jaulin, PhD received the trophee from Lise ALTER, Managing Director of the Health Innovation Agency. We are humbled to have been selected among the 177 exciting projects and 10 Grands Prix i-Lab that will be supported through #France2030. Congratulations to all of them!   Thank you to Gouvernement, ADEME, and Bpifrance for your support.   This award highlights the tremendous work of our growing team – recently shared through a publication at #ESMO24 - and will contribute to Orakl Oncology next developments.   Labelled “Grand Prix” of the Pharmacy & Biotechnology theme of #iLab, Orakl Oncology team is committed to accelerate the discovery and ensure the clinical success of new oncology drugs through a unique collection of patient tumor avatars, to bring faster better drugs to each cancer patient. This i-Lab project aims to further enhance our translational predictive capabilities and prepare the platform scale-up.   Thanks to all Oraklees and to our partners! Fanny Jaulin, PhD, Gustave Ronteix, Diane-Laure Pagès, Mia Cabantous, Gizem Altay, Julie MASSON, Jérôme Caron, Jean Bouteiller, Lélia Polit, Hugo Heinkele, Anna-Rose Gryspeert, Rafał Pietrzak, Fabiana Graziosi Gustave Roussy | Gustave Roussy Transfert | Paris Saclay Cancer Cluster (PSCC) | RHU ORGANOMIC | MATWIN | BioLabs France | HEC Challenge + | Agoranov | Speedinvest | HCVC | Verve Ventures | Fondation Lopez-Loreta | Gouvernement | Secrétariat général pour l'investissement | Ministère de l’Économie, des Finances et de la Souveraineté industrielle et numérique | Ministère de l'Enseignement supérieur et de la Recherche | Ministère de la Santé | Bpifrance | ADEME | Direction Générale des Entreprises | Direction générale de la recherche et de l'innovation (DGRI) | Agence de l'innovation en santé #innovation #oncology #cancer #drugdevelopment #startup

🎬 That's a clap! Orakl Oncology was thrilled to be at #ESMO24! It's a bit of a challenge to summarize an event of this size. Thousands of attendees, hundreds of sessions, close to two thousand posters presented. Some of our preferred highlights were the improvements in Phase 1 trial designs, the incredible explosion of ADCs and of course the continued rise of immunotherapy. This was also a chance for us to present some of our initial results regarding the use of patient-derived organoids and matched patient data to predict patient responses in the clinic (👇 see the comments for the full explainer 👇). A huge thank you to all our collaborators (and especially Gustave Roussy) and the individual clinicians and researchers who made this project possible. Fanny Jaulin, PhD Diane-Laure Pagès Gustave Ronteix Gizem Altay Anna-Rose Gryspeert Alice Boilève Michel Ducreux Jérôme Cartry Sabrina Bedja Jacques Mathieu Gustave Roussy Transfert #ESMO24 #Oncology

Fantastic talk at #ESMO24 by our CEO Fanny Jaulin, PhD on the work done at Gustave Roussy and RHU ORGANOMIC unveiling clinical trial results - use of organoids in functional precision medicine. To follow-up on the potential of tumor avatars x AI in drug development, come and visit us at poster 10P today (12-2pm) to see Orakl Oncology latest exciting results! Congrats to all collaborators! #AI #drugdevelopment #oncology Anna-Rose Gryspeert Gizem Altay Gustave Ronteix Fanny Jaulin, PhD Diane-Laure Pagès

🚀 D-day! Today is the kick-off day for #ESMO2024 Barcelona. The whole Orakl Oncology Team (Fanny Jaulin, PhD, Diane-Laure Pagès, Gustave Ronteix , Gizem Altay and Anna-Rose Gryspeert) is excited to meet you there to share ideas, discussions and projects. 🎬 We can’t wait to present you our latest scientific updates in precision oncology. Join us on Sunday, September 15th : ➡ At 10:15 AM – at Oviedo auditorium - Hall 3: Our CEO, Fanny Jaulin, PhD will talk about the use of patient-derived organoids (PDOs) in functional precision oncology.    ➡ At poster 10P, we will present initial results on the predictive power of Orakl’s technology and how it can be used to predict individual patient outcomes in the clinic. If you want to know more about us, don’t hesitate to contact us at contact@orakl-oncology.com or to reach out to the team members that will be present.   

We're very excited to attend the #ESMO2024 congress in Barcelona with part of the Orakl Oncology team (Fanny Jaulin, PhD, Diane-Laure Pagès, Gizem Altay, Anna-Rose Gryspeert, Gustave Ronteix). Don't miss the latest updates on the science in the precision oncology field with two different presentations : 🧫 Our CEO, Fanny Jaulin, PhD will be presenting a talk on the use of patient-derived organoids (PDO) in functional precision oncology on Sunday at 10:20. 🧬 You will find Orakl Oncology presenting some of our initial results on Sunday September 15 at poster 10P.